Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer.

PloS one - 1 Jan 2020

Miyamoto Yuji, Schirripa Marta, Suenaga Mitsukuni, Cao Shu, Zhang Wu, Okazaki Satoshi, Berger Martin D, Matsusaka Satoshi, Yang Dongyun, Ning Yan, Baba Hideo, Loupakis Fotios, Lonardi Sara, Pietrantonio Filippo, Borelli Beatrice, Cremolini Chiara, Yamaguchi Toshiharu, Lenz Heinz-Josef

Abstract excerpt

Activin/myostatin signaling has a critical role not only in cachexia but also in tumor angiogenesis. Cachexia is a frequent complication among patients with advanced cancer and heavily pretreated patients. We aimed to evaluate the prognostic significance of cachexia-associated genetic variants in refractory metastatic colorectal cancer (mCRC) patients treated with regorafenib. Associations between twelve single...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Forkhead Box Protein O3
Share to Myostatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Metastasis

Share to Phenylurea Compounds

Share to Proportional Hazards Models

Share to Pyridines

Share to Smad2 Protein

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 32970737
DOI: 10.1371/journal.pone.0239439
PMCID: PMC7514061

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer.PMID 32970737Read ↗

Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.Semantic proximity Read ↗

Molecular insight of regorafenib treatment for colorectal cancer.Semantic proximity Read ↗

Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancer.Semantic proximity Read ↗

[Regorafenib in patients with metastatic colorectal cancer: a review and an update].Semantic proximity Read ↗

A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials.Semantic proximity Read ↗

Durable Disease Control with Regorafenib in a Patient with Metastatic KIT-Mutated Colorectal Cancer.Semantic proximity Read ↗

The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.Semantic proximity Read ↗

Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients.Semantic proximity Read ↗

ACVR2B polymorphism, Adiponectin, and GDF-15 levels as biomarkers for cachexia in gastrointestinal cancer.Semantic proximity Read ↗

Clinical Significance of INHBA Gene Expression in Patients with Gastric Cancer who Receive Curative Resection Followed by Adjuvant S-1 ChemotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.